HK1157227A1 - Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system - Google Patents

Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system

Info

Publication number
HK1157227A1
HK1157227A1 HK11111727.4A HK11111727A HK1157227A1 HK 1157227 A1 HK1157227 A1 HK 1157227A1 HK 11111727 A HK11111727 A HK 11111727A HK 1157227 A1 HK1157227 A1 HK 1157227A1
Authority
HK
Hong Kong
Prior art keywords
deseases
butyrylcholinesterase
ligands
treatment
nervous system
Prior art date
Application number
HK11111727.4A
Other languages
English (en)
Inventor
Sultan Darvesh
Eric Joy
Earl Martin
Ian Macdonald
Ian Pottie
Original Assignee
Treventis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treventis Corp filed Critical Treventis Corp
Publication of HK1157227A1 publication Critical patent/HK1157227A1/xx

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B62LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62BHAND-PROPELLED VEHICLES, e.g. HAND CARTS OR PERAMBULATORS; SLEDGES
    • B62B3/00Hand carts having more than one axis carrying transport wheels; Steering devices therefor; Equipment therefor
    • B62B3/02Hand carts having more than one axis carrying transport wheels; Steering devices therefor; Equipment therefor involving parts being adjustable, collapsible, attachable, detachable or convertible
    • B62B3/022Hand carts having more than one axis carrying transport wheels; Steering devices therefor; Equipment therefor involving parts being adjustable, collapsible, attachable, detachable or convertible folding down the body to the wheel carriage or by retracting projecting parts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50Aroyl radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B62LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62BHAND-PROPELLED VEHICLES, e.g. HAND CARTS OR PERAMBULATORS; SLEDGES
    • B62B2202/00Indexing codes relating to type or characteristics of transported articles
    • B62B2202/40Sport articles
    • B62B2202/404Golf articles, e.g. golfbags
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B62LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62BHAND-PROPELLED VEHICLES, e.g. HAND CARTS OR PERAMBULATORS; SLEDGES
    • B62B2205/00Hand-propelled vehicles or sledges being foldable or dismountable when not in use
    • B62B2205/12Collapsible wheels
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B62LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62BHAND-PROPELLED VEHICLES, e.g. HAND CARTS OR PERAMBULATORS; SLEDGES
    • B62B2205/00Hand-propelled vehicles or sledges being foldable or dismountable when not in use
    • B62B2205/20Catches; Locking or releasing an articulation
    • B62B2205/24Catches; Locking or releasing an articulation to hold in the folded position

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Combustion & Propulsion (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11111727.4A 2008-08-29 2011-10-31 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system HK1157227A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9286108P 2008-08-29 2008-08-29
PCT/US2009/055365 WO2010025368A1 (en) 2008-08-29 2009-08-28 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system

Publications (1)

Publication Number Publication Date
HK1157227A1 true HK1157227A1 (en) 2012-06-29

Family

ID=41721953

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11111727.4A HK1157227A1 (en) 2008-08-29 2011-10-31 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system

Country Status (10)

Country Link
US (1) US8795630B2 (de)
EP (1) EP2320891B1 (de)
JP (1) JP5734853B2 (de)
CN (1) CN102164598A (de)
AU (1) AU2009285584B2 (de)
CA (1) CA2735118C (de)
HK (1) HK1157227A1 (de)
IL (1) IL211347A (de)
NZ (1) NZ591824A (de)
WO (1) WO2010025368A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150217004A1 (en) * 2012-09-05 2015-08-06 Treventis Corporation Carbamate compounds and methods of use in diseases of the nervous system
US20150290158A1 (en) * 2012-11-09 2015-10-15 Elliott C. Lasser X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions
CN106032383B (zh) * 2015-03-19 2019-08-13 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途
CN109265451B (zh) * 2018-10-09 2022-07-15 中国药科大学 丁酰胆碱酯酶选择性抑制剂及其制备方法与用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208500A1 (es) * 1972-06-14 1977-02-15 Merck & Co Inc Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
JPH0495071A (ja) 1990-08-10 1992-03-27 Kyorin Pharmaceut Co Ltd カルバミン酸誘導体
JPH06263733A (ja) 1993-01-14 1994-09-20 Sankyo Co Ltd ベンゼン誘導体
ES2255170T3 (es) * 1997-07-09 2006-06-16 Axonyx Inhibidores de butirilcolinesterasa altamente selectivos para el tratamiento y diagnostico de demencias y de la enfermedad de alzheimer.
PE20020157A1 (es) * 1999-12-03 2002-02-22 Agouron Pharma Compuestos derivados de piridona como inhibidores de proteasas de picornaviral 3c, composiciones, sus usos farmaceuticos y materiales para su sintesis
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
KR20050109505A (ko) * 2003-02-22 2005-11-21 메르크 파텐트 게엠베하 액정인 시아노피리돈 유도체
JP2006077006A (ja) 2004-08-13 2006-03-23 Eisai Co Ltd 加齢に伴う過活動膀胱治療薬
RU2423351C2 (ru) * 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors

Also Published As

Publication number Publication date
EP2320891A1 (de) 2011-05-18
CN102164598A (zh) 2011-08-24
US8795630B2 (en) 2014-08-05
CA2735118C (en) 2016-02-23
CA2735118A1 (en) 2010-03-04
JP5734853B2 (ja) 2015-06-17
WO2010025368A1 (en) 2010-03-04
US20110212026A1 (en) 2011-09-01
IL211347A (en) 2015-11-30
NZ591824A (en) 2013-07-26
EP2320891B1 (de) 2013-10-09
AU2009285584A1 (en) 2010-03-04
EP2320891A4 (de) 2011-09-28
AU2009285584B2 (en) 2015-04-02
JP2012501343A (ja) 2012-01-19

Similar Documents

Publication Publication Date Title
EP2361089A4 (de) Behandlung einer veränderten synuclein-funktion
IL204785A0 (en) Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
EP2260109A4 (de) Verfahren und zusammensetzungen auf microrna-basis zur diagnose, prognose und behandlung von erkrankungen in verbindung mit der prostata
ZA201101425B (en) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative deseases
HK1156631A1 (en) Novel compounds and methods for therapy
EP2212440A4 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von adenokarzinomen der speiseröhre
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2352515A4 (de) Verfahren zur behandlung von hämophilie
IL205562A0 (en) Benzodiazepinone compounds useful in the treatment of skin conditions
EP2300011A4 (de) Therapeutische verfahren und verbindungen
HK1149322A1 (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
HK1212218A1 (en) Organoarsenic compounds and methods for the treatment of cancer
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
HK1157227A1 (en) Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
EP2470020A4 (de) Benzodiazepinonverbindungen und behandlungsverfahren damit
GB0821501D0 (en) Method, composition, and device, for the treatment of enzymes and saccharides disorder
EP2303284A4 (de) Verfahren zur behandlung von bipolaren störungen
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0809319D0 (en) The treatment of puritus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170828